Analysts expect that Evoke Pharma Inc (NASDAQ:EVOK) will report earnings of ($0.11) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Evoke Pharma’s earnings. The lowest EPS estimate is ($0.13) and the highest is ($0.08). Evoke Pharma reported earnings of ($0.22) per share in the same quarter last year, which would suggest a positive year over year growth rate of 50%. The firm is scheduled to announce its next earnings results on Wednesday, March 6th.

On average, analysts expect that Evoke Pharma will report full-year earnings of ($0.47) per share for the current financial year, with EPS estimates ranging from ($0.48) to ($0.46). For the next fiscal year, analysts forecast that the business will report earnings of ($0.59) per share, with EPS estimates ranging from ($0.83) to ($0.34). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Evoke Pharma.

Evoke Pharma (NASDAQ:EVOK) last issued its quarterly earnings data on Tuesday, November 13th. The specialty pharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.01).

EVOK has been the subject of a number of analyst reports. Zacks Investment Research cut Evoke Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, October 17th. B. Riley reissued a “buy” rating on shares of Evoke Pharma in a report on Wednesday, November 14th. Finally, HC Wainwright set a $9.00 price objective on Evoke Pharma and gave the company a “buy” rating in a report on Monday, December 10th.

Several institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its holdings in shares of Evoke Pharma by 5.5% in the fourth quarter. BlackRock Inc. now owns 83,583 shares of the specialty pharmaceutical company’s stock valued at $207,000 after buying an additional 4,392 shares during the last quarter. Wambolt & Associates LLC bought a new position in shares of Evoke Pharma in the fourth quarter valued at about $82,000. Finally, JPMorgan Chase & Co. bought a new position in shares of Evoke Pharma in the third quarter valued at about $111,000. 18.60% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ EVOK opened at $2.88 on Wednesday. Evoke Pharma has a 52-week low of $1.85 and a 52-week high of $3.40.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is in Phase 2b clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Further Reading: Understanding each part of a balance sheet

Get a free copy of the Zacks research report on Evoke Pharma (EVOK)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with's FREE daily email newsletter.